#Germany #Fresenius Medical Care #Bad Homburg #Care Delivery #Cassie McLean

Fresenius Medical Care Appoints Cassie McLean

In a significant shift within its management structure, Fresenius Medical Care AG, the global front-runner in providing products and services for those suffering from renal disease, announced the appointment of Cassie McLean as a member of its Management Board, effective August 1, 2026. McLean steps into her role as Chief Executive Officer of the Care Delivery segment, succeeding Craig Cordola, who previously managed this crucial area.

A Dynamic Entry into Leadership

Cassie McLean brings substantial experience to her new role. She joined Fresenius Medical Care just a year ago as President of Fresenius Kidney Care, where she began fostering improvements in operational efficiency. Now, she takes on further responsibilities, becoming accountable for the global clinic business, including services in the U.S. and international markets, aimed at increasing their performance and operational execution.

Michael Sen, Chairman of the Supervisory Board, expressed confidence in Cassie's capabilities, stating, "We welcome Cassie McLean to the Management Board of Fresenius Medical Care. She brings deep dialysis expertise and a clear understanding of the performance drivers in the clinic business." This sentiment reflects a maturation of the company's focus on care delivery; McLean's appointment is seen as pivotal for accelerating innovation and accountability within the organization.

A Strong Track Record

Prior to her tenure at Fresenius, McLean was CEO of Monte Nido, a leading company in the behavioral health sector, where she specialized in treating eating disorders. Her extensive experience also includes nearly sixteen years at DaVita Kidney Care, where she climbed the ranks in various leadership positions. In addition to her professional roles, McLean holds a Master’s degree in Public Administration with a focus on Healthcare Finance from New York University, and a Bachelor of Science degree in Biology from Colorado College.

A Vision for the Future

In her new role, McLean aims to further drive the Care Delivery segment's strategic objectives. She stated, "Care Delivery is critical in serving our patients, and our goal is to improve treatment growth in the U.S. market while ensuring sustainable and profitable growth in the long term." This strategic focus is aligned with the broader ambitions of Fresenius Medical Care to deliver high-quality care consistently.

The reshaping of the Care Delivery role is designed to enforce direct accountability for operational success and effective business performance. McLean's promise to enhance the clinic's operational visibility and accountability marks a new chapter for the company.

A Commitment to Quality

Helen Giza, CEO and Chair of the Management Board at Fresenius Medical Care, lauded McLean's rapid impact since joining the firm, as she implemented new structures to bolster accountability and strengthen the talent within the clinic sector. Giza noted, "I am confident in her ability to execute our strategy and meet our mid-term financial aspirations."

As Fresenius Medical Care continues to serve roughly 4.5 million patients globally who require regular dialysis treatment, McLean’s leadership is set to play a transformative role. The organization operates a network of 3,513 clinics worldwide, delivering care for approximately 290,000 patients. Under her guidance, Fresenius Medical Care seeks to refine its operations while retaining its commitment to providing the highest standard of care.

In conclusion, Cassie McLean’s appointment is poised to enhance the operation and effectiveness of Fresenius Medical Care’s Care Delivery segment, emphasizing the company's ongoing mission to improve the lives of renal disease patients around the world.